Clinical Trial Update: Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous) for post-polio syndrome was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-polio Syndrome

Drugs mentioned

• Flebogamma 5% DIF (immune globulin intravenous (human), 5% solution (dual inactivation and filtration))

Snippet

Sponsor: Instituto Grifols, S.A. | Conditions: Post-polio Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-12-05